| 7.74 1.01 (15.01%) | 07-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.11 |
1-year : | 10.64 |
| Resists | First : | 7.8 |
Second : | 9.11 |
| Pivot price | 6.75 |
|||
| Supports | First : | 6.7 |
Second : | 6.03 |
| MAs | MA(5) : | 7.09 |
MA(20) : | 6.68 |
| MA(100) : | 6.73 |
MA(250) : | 6.34 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 78.1 |
D(3) : | 72.7 |
| RSI | RSI(14): 63.1 |
|||
| 52-week | High : | 9.53 | Low : | 4.73 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AURA ] has closed Bollinger Bands are 18.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.76 - 7.79 | 7.79 - 7.83 |
| Low: | 6.67 - 6.71 | 6.71 - 6.74 |
| Close: | 7.67 - 7.74 | 7.74 - 7.8 |
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Wed, 01 Jul 2026
Executive at Aura Biosciences (AURA) receives 14,858 RSUs - Stock Titan
Tue, 30 Jun 2026
Aura Biosciences, Inc. ($AURA) Former President, CEO and Director 2025 Pay Revealed - Quiver Quantitative
Mon, 29 Jun 2026
Form DEF 14A AURA BIOSCIENCES For: 29 June By Investing.com - Investing.com South Africa
Thu, 25 Jun 2026
Aura Biosciences Inc Actuals & Estimates (NASDAQ:AURA) - TradingView
Thu, 25 Jun 2026
AURA Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 12 Jun 2026
InvestingPro’s Fair Value spotted Aura Biosciences’ 47% decline By Investing.com - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 51 (%) |
| Shares Short | 5,390 (K) |
| Shares Short P.Month | 3,160 (K) |
| EPS | -1.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.66 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -50.6 % |
| Return on Equity (ttm) | -95.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -4.53 |
| PEG Ratio | 0 |
| Price to Book value | 4.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|